argenx Appoints Camilla Sylvest to Board of Directors
September 08, 2022 14:10 ET
|
argenx SE
September 8, 2022 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx to Present at Wells Fargo Healthcare Conference
August 31, 2022 01:00 ET
|
argenx SE
August 31, 2022Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Announces European Commission Approval of VYVGART™ (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis
August 11, 2022 07:00 ET
|
argenx SE
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in Europe for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)...
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
July 28, 2022 02:30 ET
|
argenx SE
July 28, 2022 Breda, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
July 28, 2022 01:00 ET
|
argenx SE
$75 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales from U.S. and Japan commercial launch; approval in Europe on track for third quarter 2022Biologics License...
argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022
July 21, 2022 01:00 ET
|
argenx SE
July 21, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in Europe
June 24, 2022 01:00 ET
|
argenx SE
Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measuresEuropean Commission decision on marketing...
argenx to Present at Upcoming Investor Conferences
June 01, 2022 01:00 ET
|
argenx SE
June 1, 2022Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today...
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia Gravis
May 31, 2022 01:00 ET
|
argenx SE
Positive scientific opinion under Early Access to Medicines Scheme (EAMS) will make efgartigimod available to eligible generalized myasthenia gravis (gMG) patients in the UK prior to marketing...
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases
May 19, 2022 07:00 ET
|
argenx SE
Translational data from Phase 2 study of efgartigimod in pemphigus further demonstrate argenx’s scientific leadership in FcRn biology, providing new insights into pathophysiology of autoimmune skin...